Minutia

Ownership

Private

Therapeutic Areas

Endocrinology

Stage

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Modalities

Stem cell-derived insulin-producing cellsNanosensor-enabled cell therapiesCell and gene therapy technologies[1][2][4]

Minutia General Information

Minutia has demonstrated a minimally invasive outpatient transplant procedure using insulin-producing cells with nanosensors in a PI-led Phase 1/2 clinical trial at UCSF. Early results show promising safety and proof-of-concept data, with the goal of providing a functional cure for T1D and enabling real-time monitoring of transplanted cells to improve outcomes.[2][4]

Contact Information

Website

https://www.minutia.co/

Primary Industry

Biotech

Corporate Office

Oakland, California
United States

Drug Pipeline

No pipeline data available

For full access to Minutia's pipeline data

Book a demo

Key Partnerships

Oregon Health & Sciences University (OHSU)[1]

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Minutia Funding

No funding data available

Early Stage VC (Series A)	04-Jun-2020	$38M	Completed	Phase 1
Seed Round	12-Feb-2019	$8.5M	Completed	Startup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more

To view Minutia's complete valuation and funding history, request access »